Table 3 Results of meta-analysis and quality of evidence

Clinical Efficiency Rate

2813 (28)

791 per 1000

941 per 1000

(917 to 973)

RR 1.19

(1.16 to 1.23)

0

⨁⨁⨁◯

MODERATE

Risk of bias (-1) ^a

Uterine Fibroids Volume

1902 (19)

-

MD 3.15 lower

(3.79 to 2.51 lower)

-

95

⨁◯◯◯

VERY LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b

Publication bias (-1) ^c

Uterine Volume

909 (8)

-

MD 8.56 lower

(10.99 to 6.12 lower)

-

47

⨁⨁⨁◯

MODERATE

Risk of bias (-1) ^a

Adverse drug reactions

1104 (11)

132 per 1000

104 per 1000

(77 to 145)

RR 0.79

(0.58 to 1.1)

0

⨁⨁◯◯

LOW

Risk of bias (-1) ^a

Imprecision (-1) ^d

Estradiol

2813 (28)

-

SMD 1.39 lower

(1.73 to 1.06 lower)

-

93

⨁◯◯◯

VERY LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b

Publication bias (-1) ^c

Progesterone

2258 (22)

-

SMD 1.22 lower

(1.55 to 0.89 lower)

-

92

⨁⨁◯◯

LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b

Follicle Stimulating Hormone

2540 (25)

-

SMD 1.35 lower

(1.78 to 0.93 lower)

-

96

⨁◯◯◯

VERY LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b

Publication bias (-1) ^c

Luteinizing Hormone

2440 (24)

-

SMD 1.1 lower

(1.5 to 0.71 lower)

-

95

⨁◯◯◯

VERY LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b

Publication bias (-1) ^c

Menstrual Flow

252 (3)

-

MD 27.28 lower

(43.93 to 10.63 lower)

-

93

⨁⨁◯◯

LOW

Risk of bias (-1) ^a

Inconsistency (-1) ^b